Dr. Rodney Nash, PhD – Scientific Founder
Dr. Rodney J. Nash, PhD has an extensive background in Molecular Cell Biology, particularly in the development of cellular models for human disease. Dr. Nash received his PhD from the University of Georgia where he developed methods in animal cloning and led projects developing human stem cell lines. Afterwards, he completed two Post-Doctoral Fellowships at Emory University where he developed cellular models for Fetal Alcohol Syndrome as well as Glioblastoma targeting nanoparticles. Additional cellular models were created to study HIV/Neuro AIDS, Glioblastoma Multiform, substance abuse, neuronal and hepatocellular conditions. Additional technologies include the design of media for primary cells, diagnostic testing, and methods in cellular dissociation. Dr. Nash is also a professor at Georgia State University where he contributes to the next generation of scientist as well as holding committee position at medical and government entities.
Dr. Donovan Moxey, PhD– Strategic Business Consultant
Dr. Donovan Moxey is a proven Business Executive and Technologists with more than twenty (20) years of experience working in the technology industry including new business start-ups, funded technology research, and a large multi-national technology firm. Dr. Moxey has a strong background in engnieering, and materials science, and holds a PhD in Electronic Materials Science & Engineering from North Carolina State University. Dr. Moxey is an experienced entrepreneur with an established track record of success, and experience in technology transfer and commercialization, forming strategic partnerships, business development, project management, strategic analysis and planning, new product development, product marketing, and positioning high-tech start-up companies for equity and non-equity investment. Dr. Moxey has experience and expertise in technology commercialization, developing national and international strategic alliances and partnerships, including establishing business relationships in North America, the UK, Europe, Korea, Japan, China, and The Caribbean. Dr. Moxey has experience in building executive management and cross-functional teams, and has executive level management experience with roles as Chairman, CEO, CTO, and VP of Business Development. Dr. Moxey serves in the role of strategic business consultant to JBI providing guidance and oversight with respect to its business and strategic planning, fund raising, partnering relationships, and growth strategy.
Dr, Zachary Morehouse, DO, MS – Scientific Partner
Dr. Zachary Morehouse is a board-certified physician in family medicine with advanced training in molecular and cellular biology, molecular virology, and regenerative medicine. He received his Doctor of Osteopathic Medicine from Michigan State University College of Osteopathic Medicine, Master of Science in Biology from Georgia State University, and Bachelor of Science in Biological Science from Florida State University. His research background includes graduate- level training in molecular virology, cellular recovery, and therapeutic development.
With multiple patents in molecular diagnostic testing and cellular recovery protocols, Dr. Morehouse has led biotech consulting efforts focused on optimizing sample workflows and assay platforms for both clinical and translational uses. His current research in the field of regenerative medicine integrates molecular mechanisms discovery, tissue processing optimization, and clinical outcomes to drive benchtop-to-bedside innovation. Combining molecular precision with clinical relevance, he is committed to delivering evidence-based innovations that are both scientifically validated and practically impactful for his patients.
Dr. Christopher Scharer, PhD – Scientific Partner
Dr. Christopher Scharer is a leading expert in molecular regulation of immune responses in the context of infection, vaccination, and autoimmunity. Dr. Scharer earned his B.S. from Emory University and Ph.D. from Emory University in Genetics and Molecular Biology where he studied molecular biomarkers of prostate cancer development. He completed his post-doctoral fellowship in immunology and now runs a lab focused on the mechanisms leading to the formation of antibody secreting plasma cells. He has authored more than 90 peer reviewed publications and is a leading expert in genomic sequencing and data analysis and the use of cell culture and animal models to study immune responses.